Sébastien Faraj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sébastien Faraj has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Aurora Mariani
Department of Pediatric Surgery, Angers University Hospital, Angers, France
4 shared publications Marc-David Leclair
Department of Pediatric Surgery and Urology, ordinary member of the National Reference center for Rare Urinary Tract Malformations (CRMR MARVU), CHU Nantes, Université de Nantes, Nantes, France
4 shared publicationsSabine Irtan
4 shared publications- Thomas Loubersac
Department of Pediatric Urology, Nantes University Hospital, Nantes, France
4 shared publications - Hortense Alliot
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F, Nantes, 44000, France
3 shared publications - Marc-David Leclair
Nantes Université, CHU Nantes, Department of Pediatric Urology, F-44000 Nantes, France
3 shared publications
Latest Publications
- 7 November 2026
- Published by Elsevier in European Urology Focus
What Pediatric and Adult Urologists Should Know About Genetics in CAKUT
- 7 November 2026
- Published by Elsevier in European Urology Focus
What Pediatric and Adult Urologists Should Know About Genetics in CAKUT
- Open Access
- 22 May 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (5) , 106043
Management of undescended testicle in patients with prune belly syndrome: 30 years of experience in the French cohort - A multicentric study
- 22 May 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (5) , 106043
Open AccessManagement of undescended testicle in patients with prune belly syndrome: 30 years of experience in the French cohort - A multicentric study
- 19 May 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28 (1)
Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives
High-risk neuroblastoma remains a challenging pediatric cancer, with survival rates lagging despite advances in multimodal therapy. This review aims to critically synthesize recent advances in GD2-directed chimeric antigen receptor (CAR) T cell therapy for neuroblastoma and to highlight its potential to improve long-term outcomes. In early-phase trials of GD2-directed CAR-T cell therapy for relapsed or refractory neuroblastoma, no dose-limiting toxicities were observed. Objective responses ranged from 6% to 33%, with durable complete remissions reported beyond 10 years. Stable disease occurred in up to 55% of patients. Cytokine release syndrome was reported in 0-90% of cases, generally mild, and neurotoxicity was rare. CAR-T cell expansion and trafficking to tumor sites have been demonstrated in several studies, although they remain variable and often limited in solid tumor settings. GD2-directed CAR-T cell therapy demonstrates limited but measurable clinical activity, particularly in minimal residual disease settings, with an overall acceptable safety profile. Continued innovation in CAR design and integration into multimodal strategies may improve long-term outcomes for this aggressive pediatric cancer.
- 19 May 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28 (1)
Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives
High-risk neuroblastoma remains a challenging pediatric cancer, with survival rates lagging despite advances in multimodal therapy. This review aims to critically synthesize recent advances in GD2-directed chimeric antigen receptor (CAR) T cell therapy for neuroblastoma and to highlight its potential to improve long-term outcomes. In early-phase trials of GD2-directed CAR-T cell therapy for relapsed or refractory neuroblastoma, no dose-limiting toxicities were observed. Objective responses ranged from 6% to 33%, with durable complete remissions reported beyond 10 years. Stable disease occurred in up to 55% of patients. Cytokine release syndrome was reported in 0-90% of cases, generally mild, and neurotoxicity was rare. CAR-T cell expansion and trafficking to tumor sites have been demonstrated in several studies, although they remain variable and often limited in solid tumor settings. GD2-directed CAR-T cell therapy demonstrates limited but measurable clinical activity, particularly in minimal residual disease settings, with an overall acceptable safety profile. Continued innovation in CAR design and integration into multimodal strategies may improve long-term outcomes for this aggressive pediatric cancer.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Immunochimiothérapie du neuroblastome : nouvelle thérapeutique améliorée ciblant le ganglioside GD2 O-acétylé pour le traitement des neuroblastomes chez l'enfant
Malgré les récentes avancées dans la prise en charge des neuroblastomes de haut risque, le pronostic des patients qui en sont atteints reste péjoratif. Les modalités thérapeutiques sont agressives et de nombreux enfants souffrent des effets secondaires de celles-ci, dégradant de ce fait leur qualité de vie. L’immunothérapie anti-GD2 offre dans ce contexte une alternative thérapeutique, permettant d’améliorer le pronostic de ces tumeurs, mais leur utilisation est néanmoins limitée par la présence d’une toxicité des molécules existantes. Le GD2 O-acétylé n’étant pas exprimé à la surface des fibres nerveuses périphériques, le choisir comme cible thérapeutique peut s’avérer efficace tout en diminuant la toxicité de l’immunothérapie. Nous avons vérifié l’expression du GD2 O-acétylé à la surface des cellules de 4 lignées cellulaires de neuroblastome (LAN1, LAN5, IMR5, NXS2). Cette expression n’est pas modifiée par les traitements par chimiothérapie utilisés dans les traitements des neuroblastomes de haut grade (cisplatine, doxorubicine et topotecan). Nous montrons que l’anticorps murin 8B6 spécifique du GD2 O-acétylé a une relation synergique in vitro avec les molécules de chimiothérapie testées (cisplatine, doxorubicine et topotecan). Nous montrons par la suite que cet anticorps augmente l’efficacité de la doxorubicine et du topotecan in vivo chez la souris sans diminuer la tolérance globale du traitement multimodal. Nos résultats montrent qu’un traitement combinant chimiothérapie et immunothérapie peut augmenter l’efficacité et la tolérance cliniques des chimiothérapies dans le traitement des neuroblastomes de haut grade.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Immunochimiothérapie du neuroblastome : nouvelle thérapeutique améliorée ciblant le ganglioside GD2 O-acétylé pour le traitement des neuroblastomes chez l'enfant
Malgré les récentes avancées dans la prise en charge des neuroblastomes de haut risque, le pronostic des patients qui en sont atteints reste péjoratif. Les modalités thérapeutiques sont agressives et de nombreux enfants souffrent des effets secondaires de celles-ci, dégradant de ce fait leur qualité de vie. L’immunothérapie anti-GD2 offre dans ce contexte une alternative thérapeutique, permettant d’améliorer le pronostic de ces tumeurs, mais leur utilisation est néanmoins limitée par la présence d’une toxicité des molécules existantes. Le GD2 O-acétylé n’étant pas exprimé à la surface des fibres nerveuses périphériques, le choisir comme cible thérapeutique peut s’avérer efficace tout en diminuant la toxicité de l’immunothérapie. Nous avons vérifié l’expression du GD2 O-acétylé à la surface des cellules de 4 lignées cellulaires de neuroblastome (LAN1, LAN5, IMR5, NXS2). Cette expression n’est pas modifiée par les traitements par chimiothérapie utilisés dans les traitements des neuroblastomes de haut grade (cisplatine, doxorubicine et topotecan). Nous montrons que l’anticorps murin 8B6 spécifique du GD2 O-acétylé a une relation synergique in vitro avec les molécules de chimiothérapie testées (cisplatine, doxorubicine et topotecan). Nous montrons par la suite que cet anticorps augmente l’efficacité de la doxorubicine et du topotecan in vivo chez la souris sans diminuer la tolérance globale du traitement multimodal. Nos résultats montrent qu’un traitement combinant chimiothérapie et immunothérapie peut augmenter l’efficacité et la tolérance cliniques des chimiothérapies dans le traitement des neuroblastomes de haut grade.
- 24 November 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 719
Artificial intelligence chatbots vs. YPUC pediatric urologists: performance on a Campbell Walsh urology hypospadiology questionnaire
Purpose Artificial intelligence (AI) is increasingly used in medicine, with uncertain performance in highly specialized fields, like hypospadiology. This study aimed to compare the performance of AI platforms and pediatric urologists using a structured knowledge assessment. Methods A 31-question multiple-choice questionnaire (12th edition of Campbell Walsh Urology) was completed by 23 members of the Young Pediatric Urologist Committee (YPUC) of the European Society for Paediatric Urology (ESPU), and by five AI models (ChatGPT 3.5, ChatGPT 4o, Gemini, Copilot, and Doubao). Scores were analyzed overall, by subgroups (FEAPU-certified (Fellow of the European Academy of Paediatric Urology, n=15), >35 years old (n=16), and self-declared hypospadiology experts (n=12)), and across four thematic categories : basics, clinical and paraclinical evaluation, initial management, and complications. Results AI and human respondents showed comparable overall performance (67.7% vs. 61.2%, p=0.467). However, experienced subgroups outperformed their counterparts: FEAPU-certified vs. non-certified (61.3% vs. 53.2%, p=0.001), >35 vs. ≤35 years (61.3% vs. 54.8%, p=0.039), and self declared experts vs. non-experts (61.3% vs. 54.8%, p=0.039). AI performed better in Basics (83% vs. 67%, p=0.320), Initial management (71% vs. 57%, p=0.450), and Complications (64% vs. 55%, p=0.087), but underperformed significantly in Clinical and paraclinical evaluation (57% vs. 71%, p=0.003). The highly specialized nature of the topic limits generalizability to broader medical contexts. Conclusion AI platforms achieved scores comparable to pediatric urologists in a structured questionnaire but fell short in domains requiring nuanced clinical reasoning. While AI shows potential as an educational-support tool, it does not replace expert human judgment in hypospadiology.
- 24 November 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 719
Artificial intelligence chatbots vs. YPUC pediatric urologists: performance on a Campbell Walsh urology hypospadiology questionnaire
Purpose Artificial intelligence (AI) is increasingly used in medicine, with uncertain performance in highly specialized fields, like hypospadiology. This study aimed to compare the performance of AI platforms and pediatric urologists using a structured knowledge assessment. Methods A 31-question multiple-choice questionnaire (12th edition of Campbell Walsh Urology) was completed by 23 members of the Young Pediatric Urologist Committee (YPUC) of the European Society for Paediatric Urology (ESPU), and by five AI models (ChatGPT 3.5, ChatGPT 4o, Gemini, Copilot, and Doubao). Scores were analyzed overall, by subgroups (FEAPU-certified (Fellow of the European Academy of Paediatric Urology, n=15), >35 years old (n=16), and self-declared hypospadiology experts (n=12)), and across four thematic categories : basics, clinical and paraclinical evaluation, initial management, and complications. Results AI and human respondents showed comparable overall performance (67.7% vs. 61.2%, p=0.467). However, experienced subgroups outperformed their counterparts: FEAPU-certified vs. non-certified (61.3% vs. 53.2%, p=0.001), >35 vs. ≤35 years (61.3% vs. 54.8%, p=0.039), and self declared experts vs. non-experts (61.3% vs. 54.8%, p=0.039). AI performed better in Basics (83% vs. 67%, p=0.320), Initial management (71% vs. 57%, p=0.450), and Complications (64% vs. 55%, p=0.087), but underperformed significantly in Clinical and paraclinical evaluation (57% vs. 71%, p=0.003). The highly specialized nature of the topic limits generalizability to broader medical contexts. Conclusion AI platforms achieved scores comparable to pediatric urologists in a structured questionnaire but fell short in domains requiring nuanced clinical reasoning. While AI shows potential as an educational-support tool, it does not replace expert human judgment in hypospadiology.
- 22 November 2025
- Published by Elsevier in Journal of Pediatric Surgery
- p. 162823
Extracorporeal membrane oxygenation (ECMO) in neonates with severe uropathies: A single-center experience
- 22 November 2025
- Published by Elsevier in Journal of Pediatric Surgery
- p. 162823
Extracorporeal membrane oxygenation (ECMO) in neonates with severe uropathies: A single-center experience
- 4 March 2025
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (5) , 1203-1208
Use of Black-Star® magnetic-end double-J stent in transperitoneal and retroperitoneal pediatric robotic assisted laparoscopic pyeloplasty
- 4 March 2025
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (5) , 1203-1208
Use of Black-Star® magnetic-end double-J stent in transperitoneal and retroperitoneal pediatric robotic assisted laparoscopic pyeloplasty
- Open Access
- 12 February 2025
- Published by Wiley
Intrapelvic Tumor Height (ITH) as a Promising Novel Prognostic Indicator for long-term functional outcomes in Sacrococcygeal Teratomas
Background: Sacrococcygeal teratoma (SCT) is considered the most common congenital neoplasm in neonates. This study aimed to assess long-term impacts on urinary and anorectal functions and quality of life (QoL) in patients who underwent surgery for SCT and to identify predictive factors for these outcomes, with a focus on the Intrapelvic Tumor Height (ITH). Methods : This retrospective study included patients treated surgically for SCT, between 1984 and 2017 at the Armand Trousseau Hospital. Urologic and anorectal functions were evaluated through clinical assessments and patient-reported outcomes through questionnaires. Statistical analysis was performed to explore correlations between these factors and long-term functional outcomes. Results: Twenty-six patients (median age=17 years) were identified. With a median follow-up of 180 months [96-444 months], 12 patients (46%) presented functional impairments: seven had isolated anorectal dysfunction and five had both urinary and anorectal dysfunctions, including neurogenic bladder (n=2) and/or detrusor-sphincter dyssynergia (n=3). A significant correlation was observed between adverse outcomes and intrapelvic tumor height (ITH) (median ITH was 27 mm in patients with impairments versus 15 mm in those without, pConclusions: This study highlights that long-term urologic and anorectal dysfunctions are prevalent in patients treated for SCT, although the overall impact on quality of life remains moderate. Importantly, ITH emerged as a more objective and accurate predictor of functional outcomes than tumor size or Altman classification.
- 12 February 2025
- Published by Wiley
Open AccessIntrapelvic Tumor Height (ITH) as a Promising Novel Prognostic Indicator for long-term functional outcomes in Sacrococcygeal Teratomas
Background: Sacrococcygeal teratoma (SCT) is considered the most common congenital neoplasm in neonates. This study aimed to assess long-term impacts on urinary and anorectal functions and quality of life (QoL) in patients who underwent surgery for SCT and to identify predictive factors for these outcomes, with a focus on the Intrapelvic Tumor Height (ITH). Methods : This retrospective study included patients treated surgically for SCT, between 1984 and 2017 at the Armand Trousseau Hospital. Urologic and anorectal functions were evaluated through clinical assessments and patient-reported outcomes through questionnaires. Statistical analysis was performed to explore correlations between these factors and long-term functional outcomes. Results: Twenty-six patients (median age=17 years) were identified. With a median follow-up of 180 months [96-444 months], 12 patients (46%) presented functional impairments: seven had isolated anorectal dysfunction and five had both urinary and anorectal dysfunctions, including neurogenic bladder (n=2) and/or detrusor-sphincter dyssynergia (n=3). A significant correlation was observed between adverse outcomes and intrapelvic tumor height (ITH) (median ITH was 27 mm in patients with impairments versus 15 mm in those without, pConclusions: This study highlights that long-term urologic and anorectal dysfunctions are prevalent in patients treated for SCT, although the overall impact on quality of life remains moderate. Importantly, ITH emerged as a more objective and accurate predictor of functional outcomes than tumor size or Altman classification.
- 7 February 2025
- Published by Elsevier in The French Journal of Urology
- Vol. 35 (5) , 102863
Long-term outcomes of “clam” bladder augmentation in a pediatric population with neurogenic refractory bladder dysfunction: A 20-year follow-up experience at single center
- 7 February 2025
- Published by Elsevier in The French Journal of Urology
- Vol. 35 (5) , 102863
Long-term outcomes of “clam” bladder augmentation in a pediatric population with neurogenic refractory bladder dysfunction: A 20-year follow-up experience at single center